Immatics N.V. revenue breakdown overview

Immatics N.V. revenue for the last year amounted to 161.32 M USD, the most of which — 168.57 M USD — came from its highest performing source at the moment, T Cell Redirecting Immunotherapies, the year earlier bringing 58.38 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Immatics N.V. 152.39 M USD, and the year before that — 60.61 M USD.